Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Falls Church, Virginia Clinical Trials

A listing of Falls Church, Virginia clinical trials actively recruiting patient volunteers.

RESULTS

Found (208) clinical trials

Phase 1 Safety Study of ACT-PFK-158 2HCl in Patients With Advanced Solid Malignancies

ACT-PFK-158 is a novel anti-cancer agent that inhibits glucose uptake in cancer cells. The primary objective of the study will be to determine the maximum tolerated dose (MTD) and to describe any dose limiting toxicity. The secondary objectives of the study will be to determine the safety profile of the ...

Phase

5.66 miles

Learn More »

Bispecific Antibody in Finding Tumor Cells in Patients With Colorectal Cancer

OBJECTIVES: - Assess the pharmacokinetics and tissue distribution of anti-CEA x anti-HSG bispecific monoclonal antibody TF2 in patients with colorectal cancer. OUTLINE: This is a multicenter study. Patients receive iodine I 131-labeled anti-CEA x anti-HSG bispecific monoclonal antibody TF2 (^131I-TF2) IV over 10-20 minutes on day 1. Patients also undergo ...

Phase

5.66 miles

Learn More »

Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure

PRIMARY OBJECTIVE: I. To assess safety, tolerability, and identify the maximum tolerated dose (MTD) of entinostat given in combination with MK-3475 (pembrolizumab). SECONDARY OBJECTIVE: I. To obtain a preliminary estimate of efficacy of entinostat in combination with MK-3475 (pembrolizumab). EXPLORATORY OBJECTIVE: I. To assess the dynamic quantitative change in measurable ...

Phase

5.66 miles

Learn More »

Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

PRIMARY OBJECTIVES: I. To establish the safety, tolerability, and the maximum tolerated dose of the combination of onalespib and AT7519M (CDKI AT7519). SECONDARY OBJECTIVES: I. To determine the pharmacokinetics of the combination of onalespib and AT7519M. II. To assess the pharmacodynamic effect of the combination of onalespib and AT7519M on ...

Phase

5.66 miles

Learn More »

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

PRIMARY OBJECTIVE: I. To determine the safety and tolerability of osimertinib (AZD9291) in combination with necitumumab in patients with EGFR-mutant non-small cell lung cancer (NSCLC). SECONDARY OBJECTIVE: I. To observe and record anti-tumor activity in these NSCLC patients in select cohorts of patients with EGFR-activating mutations including EGFR Exon 20 ...

Phase

5.66 miles

Learn More »

A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of RO7198457 as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody).

Phase

5.66 miles

Learn More »

PRS-343 in HER2-Positive Solid Tumors

The study will evaluate PRS-343 administered by intravenous (IV) infusion every 3 weeks (Schedule 1) initially. If safety, PK, and PD data suggest a different dosing schedule should be evaluated, Schedule 2 or 3 (dosing every 2 weeks or every 4 weeks in a 28-day cycle, respectively) may be conducted. ...

Phase

5.66 miles

Learn More »

A Study To Investigate The Pharmacokinetics Safety And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis

This study will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to patients with multiple sclerosis (MS).

Phase

5.66 miles

Learn More »

Nilotinib in Huntington's Disease

The investigators performed an open label phase I clinical trial using two commercially available doses of Nilotinib (150 and 300mg capsules) in patients with advanced PDD and DLB. These indications have some overlapping pathologies and clinical symptoms and share common plasma and CSF biomarkers, including alpha-Synuclein, Abeta42/40, total Tau and ...

Phase

5.66 miles

Learn More »

Study to Evaluate a Single Dose of Apixaban in Pediatric Subjects at Risk for a Thrombotic Disorder

CV185118 is a single dose Apixaban PK/PD study in pediatric subjects. The objective of this study is primarily to study the PK/PD of Apixaban in pediatric subjects at risk for thrombosis

Phase

5.66 miles

Learn More »